-496-4236.
Resources:
Framingham Heart Study, http://www.nhlbi.nih.gov/about/framingham/index.html
Your Guide to a Healthy Heart,
http://www.nhlbi.nih.gov/health/public/heart/other/your_guide/healthyheart.htm
Part of the National Institutes of Health, the National Heart,
Lung, and Blood Institute (NHLBI) plans, conducts, and supports
research related to the causes, prevention, diagnosis, and
treatment of heart, blood vessel, lung, and blood diseases; and
sleep disorders. The Institute also administers national health
education campaigns on women and heart disease, healthy weight for
children, and other topics. NHLBI press releases and other
materials are available online at: www.nhlbi.nih.gov.
NHLBI is part of the National Institutes of Health (NIH), the
Federal Government's primary agency for biomedical and behavioral
research. NIH is a component of the U.S. Department of Health and
Human Services. NHLBI press releases and other materials including
information about heart disease, high blood pressure, and high
blood cholesterol are available online at www.nhlbi.nih.gov.
The National Institutes of Health (NIH) — The Nation's
Medical Research Agency — includes 27 Institutes and Centers
and is a component of the U.S. Department of Health and Human
Services. It is the primary federal agency for conducting and
supporting basic, clinical and translational medical research, and
it investigates the causes, treatments, and cures for both common
and rare diseases. For more information about NIH and its programs,
visit www.nih.gov.
CONTACT:
NH
'"/>
Page: 1 2 3 Related medicine technology :1.
Accentia Biopharmaceuticals Scientific Presentations Demonstrate
Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at
the Annual Meeting of the American Academy of Allergy, Asthma, and
Immunology2.
AVI BioPharma Partner Cook Medical Announces Completion of Patient
Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of
Cardiovascular Disease3.
Phase IIIb Clinical Data Validate the Overall and Cardiovascular
Safety Profile of Cycloset (A Quick Release Formulation of
Bromocriptine Mesylate) in Patients with Type 2 Diabetes4.
Byetta Treatment for Three and a Half Years Associated with
Reductions in Cardiovascular Risk Factors in People with Type 2
Diabetes5.
New Analysis of WHI Data Shows Reduced Levels of Coronary Artery
Calcification, a Predictor of Cardiovascular Events, in Women aged
50-59 taking Estrogen Therapy6.
Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure
Reduction During Important Early Morning Period When Most Adverse
Cardiovascular Events Occur7.
Newly Published Data from Large Study Support Cardiovascular Safety
of Avandia (Rosiglitazone Maleate)8.
Interim Data From RECORD Study Show No Significant Difference
Between Avandia and Standard Therapy in Risk of Cardiovascular
Hospitalization or Death9.
Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events
in Landmark Jikei Heart Study10.
Diovan Achieved 40% Reduction in Stroke and Cardiovascular Events
in Landmark Jikei Heart Study11.
New Data Show Xenical Significantly Reduces Cardiovascular Risk and
More Than Doubles Weight Loss Achieved in Overweight and Obese
People